USP22 and hepatocellular carcinoma: Additionally, USP22 downregulates transferrin receptor (TFRC) transcription by removing H2B lysine 120 ubiquitination (H2BK120ub) from TFRC transcription start site (TSS) downstream region, thereby inhibiting Sorafenib‐induced ferroptosis in hepatocellular carcinoma.